Shares of Coherus Biosciences Inc (NASDAQ:CHRS) have earned an average recommendation of “Buy” from the eleven analysts that are currently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $32.00.
CHRS has been the subject of a number of research analyst reports. BidaskClub upgraded Coherus Biosciences from a “hold” rating to a “buy” rating in a report on Saturday, January 13th. Zacks Investment Research cut Coherus Biosciences from a “buy” rating to a “hold” rating in a report on Tuesday, January 9th. ValuEngine cut Coherus Biosciences from a “sell” rating to a “strong sell” rating in a report on Friday, November 10th. Finally, Citigroup reiterated a “buy” rating and set a $23.00 price target on shares of Coherus Biosciences in a report on Tuesday, November 7th.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Teacher Retirement System of Texas purchased a new position in shares of Coherus Biosciences during the 4th quarter worth $101,000. Landscape Capital Management L.L.C. acquired a new position in Coherus Biosciences during the 4th quarter worth about $116,000. Legal & General Group Plc lifted its stake in Coherus Biosciences by 12.6% during the 2nd quarter. Legal & General Group Plc now owns 9,341 shares of the biotechnology company’s stock worth $134,000 after acquiring an additional 1,046 shares in the last quarter. Bank of Montreal Can acquired a new position in Coherus Biosciences during the 4th quarter worth about $135,000. Finally, Ladenburg Thalmann Financial Services Inc. lifted its stake in Coherus Biosciences by 497.4% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 12,600 shares of the biotechnology company’s stock worth $168,000 after acquiring an additional 10,491 shares in the last quarter. Institutional investors and hedge funds own 82.46% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://stocknewstimes.com/2018/02/19/coherus-biosciences-inc-chrs-given-consensus-recommendation-of-buy-by-brokerages.html.
Coherus Biosciences Company Profile
Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.
Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.